Shots:
- Rhythm Pharmaceuticals reported the commercial launch of IMCIVREE (setmelanotide) in Japan for pts. with acquired hypothalamic obesity (HO), following its inclusion on Japan’s National Health Insurance drug price list
- IMCIVREE is the first approved therapy in Japan for acquired HO which was approved in August 2026 by Japan’s MHLW, and supported by the P-III (TRANSCEND) study data
- The TRANSCEND study enrolled 142 pts., including 12 from a Japanese cohort and 10 supplemental pts. and demonstrated an 18.8% PBO-adjusted reduction in BMI
Ref: Rhythm | Image: Rhythm | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
